Dried nanoparticle compositions
US-2024216274-A1 · Jul 4, 2024 · US
US10709666B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10709666-B2 |
| Application number | US-202016776020-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 29, 2020 |
| Priority date | May 17, 2017 |
| Publication date | Jul 14, 2020 |
| Grant date | Jul 14, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Carrier particles in the form of granules described herein are suitable for use in dry powder formulations for inhalation, and preferably administering high-strength dose active ingredients.
Opening claim text (preview).
The invention claimed is: 1. A process for preparing a granule of a physiologically acceptable excipient to be used as a carrier for dry powder formulations for inhalation, said granule having a mass diameter of from 200 to 800 micrometers and having on its surface pores with a perimeter from 70 to 300 micrometers and a diameter from 30 to 100 micrometers, a specific surface area of 0.13 to 0.20 m 2 /g, and a loading capacity equal or higher than 35%, wherein said physiologically acceptable excipient is selected from the group consisting of lactose, mannitol, trehalose, dextran, glucose, and mixtures thereof; wherein said granule has a friability of less than 3%, said process comprising the following steps: (i) selecting particles of a physiologically acceptable excipient having a starting median volume diameter of at least 100 micrometers; (ii) preparing an oversaturated aqueous solution comprising part of said physiologically acceptable excipient having a concentration in water of from 30 to 50% w/v; (iii) wetting the remaining part of said physiologically acceptable excipient with 10 to 25% w/w of said aqueous solution obtained in (ii), to obtain a mixture; (iv) stirring said mixture obtain a slurry; (v) forcing said slurry through a sieve, to obtain a wet mass; and (vi) drying said wet mass to obtain said granules. 2. The process according to claim 1 , wherein said (vi) drying is performed in a microwave or in an oven under vacuum.
Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title
substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title
Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules · CPC title
with organic compounds · CPC title
for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.